Neuropharmacology - Alzheimer's Disease Research

Lars NilssonGroup leader
Lars Nilsson
Group leader

The prevalence of neurodegenerative disorders is increasing due to an aging population. In Alzheimer’s disease (AD), the most common dementia disorder, there is an imbalance in the production and clearance amyloid-β and tau leading to protein aggregate accumulation in the brain. We have taken an interest in new genetic discoveries on sporadic AD, suggesting that additional pathogenic mechanisms are critical.

The research group mainly explores mechanisms of neuroinflammation and lipid biology to find targets for therapeutic intervention. Another interest is to find improved methods, animal and/or cell-based assays, to evaluate and try to predict effects of drug intervention. We also do collaborative biomarker studies on dementia with clinical research environments, at Akershus and Oslo University Hospital.

Research projects

  • Impact of innate immunity, specifically TREM2-biology in Alzheimer’s disease
  • Role of Apolipoprotein E in Alzheimer’s disease

Contact information:
Group leader Professor Lars Nilsson, Department of Pharmacology University Oslo/Oslo University Hospital, Postboks 1057, Blindern NO-0316 Oslo, Norway.
Tel: +47 22840221, E-mail: